The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy
Clinical and Molecular Hepatology
;
: 319-326, 2016.
Article
in English
| WPRIM
| ID: wpr-93973
ABSTRACT
Hepatocellular carcinoma (HCC) is a primary concern for patients with chronic hepatitis B (CHB). Antiviral therapy has been reasonably the focus of interest for HCC prevention, with most studies reporting on the role of the chronologically preceding agents, interferon-alfa and lamivudine. The impact of interferon-alfa on the incidence of HCC is clearer in Asian patients and those with compensated cirrhosis, as several meta-analyses have consistently shown HCC risk reduction, compared to untreated patients. Nucleos(t)ide analogues also seem to have a favorable impact on the HCC incidence when data from randomized or matched controlled studies are considered. Given that the high-genetic barrier agents, entecavir and tenofovir, are mainly used in CHB because of their favorable effects on the overall long-term outcome of such patients, the most clinically important challenge is the identification of patients who require close HCC surveillance despite on-therapy virological remission. Several risk scores have been developed for HCC prediction in CHB patients. Most of them, such as GAG-HCC, CU-HCC and REACH-B, have been developed and validated in Asian untreated and treated CHB patients, but they do not seem to offer good predictability in Caucasian CHB patients for whom a newer score, PAGE-B, has been recently developed.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Antiviral Agents
/
Risk Factors
/
Interferon-alpha
/
Carcinoma, Hepatocellular
/
Hepatitis B, Chronic
/
Liver Cirrhosis
/
Liver Neoplasms
/
Nucleotides
Type of study:
Controlled clinical trial
/
Etiology study
/
Prognostic study
/
Risk factors
Limits:
Humans
Language:
English
Journal:
Clinical and Molecular Hepatology
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS